Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | RARA | P10276 | 6/20 | 0.67 |
| ▸ | RXRA | P19793 | 5/20 | 0.67 |
| ▸ | RARB | P10826 | 4/20 | 0.67 |
| ▸ | RARG | P13631 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | RXRB | P28702 | 2/20 | 0.67 |
| ▸ | RXRG | P48443 | 2/20 | 0.67 |
| ▸ | RORC | P51449 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127846 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL23356521 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1718339 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL3500196 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1765991 | 0.90 | MAPT (0.82) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1765989 | 0.90 | MAPT (0.82) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL21140941 | 0.89 | ALDH1A1 (0.80) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1498298 | 0.88 | MAPT (0.79) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL13903879 | 0.87 | MAPT (0.77) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL3701619 | 0.87 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2RARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240103007-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | PROTEAS BIOANALYTICS, INC. (US) | 2024-03-28 | — | — | US | claimed |
| US-20240000741-A1 | ALL-TRANS RETINOIC ACID ENHANCES RADIOTHERAPY AND OVERCOMES IMMUNE SUPPRESSION FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-04 | — | — | US | claimed |
| EP-4264274-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | Proteas Bioanalytics, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2022132834-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | PROTEAS BIOANALYTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-8420610-B2 | Polyunsaturated compounds, method for preparing same and compositions containing the same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-04-16 | — | — | US | claimed |
| EP-1968993-B1 | NOVEL POLYUNSATURATED COMPOUNDS, METHOD FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAME | FABRE PIERRE DERMO COSMETIQUE (FR) | 2012-01-11 | — | — | EP | claimed |
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-07-01 | — | — | US | claimed |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-12-10 | — | — | US | claimed |
| WO-2009147400-A1 | STEM CELL CULTURE MEDIA AND METHODS | ITI SCOTLAND LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| WO-1999037150-A1 | TRANSCRIPTION THERAPY FOR CANCERS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-07-29 | — | — | WO | claimed |
| EP-0708648-A4 | INHIBITION OF TUMOR NECROSIS FACTOR AND NITRIC OXIDE PRODUCTION BY RETINOIC ACID | RES DEV FOUNDATION (US) | 1998-01-14 | — | — | EP | claimed |
| US-5658949-A | Inhibition of tumor necrosis factor by retinoic acid | RESEARCH DEVELOPMENT FOUNDATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0708648-A1 | INHIBITION OF TUMOR NECROSIS FACTOR AND NITRIC OXIDE PRODUCTION BY RETINOIC ACID | RESEARCH DEVELOPMENT FOUNDATION (US) | 1996-05-01 | — | — | EP | claimed |
| US-5457129-A | Treatment of pathophysiological diseases | RESEARCH DEVELOPMENT FOUNDATION (US) | 1995-10-10 | — | — | US | claimed |
| WO-1994026277-A1 | INHIBITION OF TUMOR NECROSIS FACTOR AND NITRIC OXIDE PRODUCTION BY RETINOIC ACID | RESEARCH DEVELOPMENT FOUNDATION (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0071598-B1 | THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS | BAZZANO, Gail S (US) | 1990-05-09 | — | — | EP | claimed |
| EP-0004680-B1 | DERIVATIVE NONATETRAENOIC ACID AND PHARMACEUTICAL COMPOSITIONS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-10-14 | — | — | EP | claimed |
| EP-0004680-A2 | Derivative nonatetraenoic acid and pharmaceutical compositions | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-10-17 | — | — | EP | claimed |
| US-4169103-A | 9-(2,2,5-TRIMETHYL-4-HYDROXY-1-CYCLOHEXENYL)-3,7-DIMETHYL -2,4,6,8-NONATETRAENOIC ACID ANTITUMOR AND ANTICARCINOGENIC AGENT | HOFFMANN-LA ROCHE INC. (US) | 1979-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | CBR3, CBR1, DECR1 | ALDH1A1 396/4885MAPT 4344/4885SMN1; SMN2 2880/4885 |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | FASN, ALOX5, ALOX15B | ALDH1A1 277/4885MAPT 2405/4885SMN1; SMN2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.